Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
May 22 2024 - 12:03PM
Business Wire
Immunis, Inc., a clinical-stage biotech developing innovative
secretome therapies to address age-related disease and immune
dysfunction, obtained a significant strategic milestone in
partnering with Toray, a Japanese drug company part of the Toray
Group. Founded in 1926, Toray has grown into a highly successful
conglomerate known for its commitment to solving pressing global
health and environmental challenges. With its production of various
advanced material sciences, Toray has diversified expertise in
industries including pharmaceuticals, electronics, textiles, and
aerospace.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240522866796/en/
(Photo: Business Wire)
Immunis licensed development and commercial rights to the
Japan-commercially-approved drug called TRK-820, an opioid receptor
agonist developed initially for the treatment of pruritus or sever
itching. Immunis’ formulation of TRK-820 shows pre-clinical
benefits for sarcopenia, and may serve as a promising
pharmaceutical complement to IMMUNA, Immunis’ human-derived
regenerative biologic published to reverse age-related muscle loss,
promote muscle growth and function, and enhance metabolism.
Immunis is currently conducting independent validations to
measure the efficacy of TRK-820 in reversing sarcopenia and will
apply for a Phase 2 clinical trial to assess efficacy in humans.
The advantages of adding TRK-820 to Immunis’ portfolio are that it
can be taken orally and that it offers a different mechanism of
action than IMMUNA to potentially enhance muscle regeneration in
humans.
Both Immunis and Toray operate with the mission of advancing
human healthcare and enhancing quality of life. Immunis is excited
by the opportunities that this partnership can offer, and we hope
to successfully address sarcopenia as a united front.
About Immunis Inc.
Immunis is a private biotechnology company developing a novel
immunomodulatory secretome product for the various manifestations
of age and disease-related immune decline. The investigational
product line leverages Immunis’ leading-edge capabilities in
secretome technology to deliver a product of all natural, all human
immune modulators in their natural relative physiological
concentrations. For additional information about Immunis’ Phase
1/2a clinical trial please visit:
https://immunisbiomedical.com/clinical-trials/
Cautionary Note Regarding
Forward-Looking Statements
This communication contains statements that constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as applicable.
Forward-looking statements include, but are not limited to,
statements regarding our plans, beliefs, expectations and
assumptions, as well as other statements that are not necessarily
historical facts. You are cautioned that these forward-looking
statements are only predictions and involve risks and
uncertainties. Further, any forward-looking statement speaks only
as of the date as of which it is made, and we do not intend to
update or revise any forward-looking statements. This communication
also contains market data related to our business and industry
which includes projections that are based on several assumptions we
believe are reasonable and most significant to the projections as
of the date of this communication. If any of our assumptions prove
to be incorrect, our actual results may significantly differ from
our projections based on these assumptions. This communication is
neither an offer to sell nor a solicitation of an offer to buy any
of the securities described herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522866796/en/
contact@immunisbiomedical.com